Dyadic and phibro animal health announce exclusive license agreement to develop and commercialize animal health vaccine

The exclusive license agreement between dyadic and phibro utilizes dyadic engineered c1-cells to produce specific targeted antigens for development and commercialization of a poultry vaccine for a targeted disease. the exclusive license agreement between dyadic and phibro utilizes dyadic engineered c1-cells to produce specific targeted antigens for development and commercialization of a poultry vaccine for a targeted disease.
DYAI Ratings Summary
DYAI Quant Ranking